ABBOTT LABORATORIES
At today's price, ABBOTT LABORATORIES (ABT) is priced for +9.6% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- Abbott is one of the most diversified names in healthcare, spread across medical devices, diagnostics, nutrition, and established pharmaceuticals, with no single segment dominating except Diabetes Care at about 18%. That breadth is the defining feature and the reason it trades like a quality compounder rather than a single-product bet. - At $88 (as of June 27, 2026) the market pays about 25 times operating income, implying roughly 8.7% annual operating growth for five years. That is within wha
Is ABT overvalued? See what's priced in →
3,016 institutional managers reported holding ABT in 13F filings for the quarter ended 2026-03-31. Together they hold about 77% of the company; the top 10 hold 38%. 138 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 22.0M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (1.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ABT has cut its share count 2.1% over the past five years, spending $8.94B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 12 years straight; the current rate is $2.40 a share annually. Cash returned over the past three years: $10.83B in dividends and $2.63B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ABT over the trailing three years: 2026: 4 buys totaling $3.28M. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ABT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +6.5% | -10.0% |
| 2023-11-02 | +3.6% | +15.7% |
| 2024-02-17 | +1.3% | -5.9% |
| 2024-05-03 | -0.1% | -1.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ABT's latest 8-K filings: 2026-04-27 (items 5.02, 5.03, 5.07, 9.01); 2026-04-17 (items 8.01, 9.01); 2026-04-16 (items 2.02, 9.01); 2026-03-23 (items 8.01, 9.01); 2026-03-09 (items 1.01, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.